Ask AI
Bill115th CongressFiled May 4, 2017Health
S. 1052

BENEFIT Act of 2017

Bill journey · stage 2 of 5

Under committee review

Filed
Comm.
Floor
Both
Law

What it doesSummary passed senate without amendment (Aug 3, 2017)

(This measure has not been amended since it was introduced. The summary has been expanded because action occurred on the measure.)

Better Empowerment Now to Enhance Framework and Improve Treatments Act of 2017 or the BENEFIT Act of 2017

(Sec. 2) This bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration (FDA) to consider patient-focused drug development data, such as patient preferences, patient-reported outcomes, and patient experiences, as part of the risk-benefit assessment of new drugs. Following approval of a drug, the FDA must include a description of how this information was considered in its statement of patient experience.

What just happenedAug 11, 2017

Referred to the Subcommittee on Health.

Who’s behind it

Sen. Wicker, Roger F. [R-MS](R-MS)Sponsor
1 cosponsor1 D
Read on Congress.gov
1cosponsors2committees10actions3subjects
  1. Aug 11, 2017Committee

    Referred to the Subcommittee on Health.

    Health Subcommittee
  2. Aug 4, 2017IntroReferralH11100

    Referred to the House Committee on Energy and Commerce.

    Energy and Commerce Committee
  3. Aug 4, 2017FloorH14000

    Received in the House.

  4. Aug 3, 2017Floor

    Message on Senate action sent to the House.

  5. Aug 3, 2017Floor

    Passed Senate without amendment by Unanimous Consent. (text: CR S4788)

  6. Aug 3, 2017Floor17000

    Passed/agreed to in Senate: Passed Senate without amendment by Unanimous Consent.(text: CR S4788)

  7. Aug 3, 2017Discharge

    Senate Committee on Health, Education, Labor, and Pensions discharged by Unanimous Consent. (consideration: CR S4787-4788)

    Health, Education, Labor, and Pensions Committee
  8. Aug 3, 2017Committee14500

    Senate Committee on Health, Education, Labor, and Pensions discharged by Unanimous Consent.(consideration: CR S4787-4788)

    Health, Education, Labor, and Pensions Committee
  9. May 4, 2017IntroReferral

    Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

    Health, Education, Labor, and Pensions Committee
  10. May 4, 2017IntroReferral10000

    Introduced in Senate

Passed Senate without amendmentAug 3, 201782

(This measure has not been amended since it was introduced. The summary has been expanded because action occurred on the measure.)

Better Empowerment Now to Enhance Framework and Improve Treatments Act of 2017 or the BENEFIT Act of 2017

(Sec. 2) This bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration (FDA) to consider patient-focused drug development data, such as patient preferences, patient-reported outcomes, and patient experiences, as part of the risk-benefit assessment of new drugs. Following approval of a drug, the FDA must include a description of how this information was considered in its statement of patient experience.
Introduced in SenateMay 4, 2017

Better Empowerment Now to Enhance Framework and Improve Treatments Act of 2017 or the BENEFIT Act of 2017

This bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration (FDA) to consider patient-focused drug development data, such as patient preferences, patient-reported outcomes, and patient experiences, as part of the risk-benefit assessment of new drugs. Following approval of a drug, the FDA must include a description of how this information was considered in its statement of patient experience.
BENEFIT Act of 2017 — Informed